DOCSLIB.ORG

Curriculum Vitae Eleftherios P. Diamandis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae Eleftherios P. Diamandis Curriculum Vitae Eleftherios P. Diamandis Revised April 28, 2017 Department of Pathology Department of Clinical Biochemistry Department of Laboratory Medicine and Laboratory Medicine University Health Network and Pathobiology Mount Sinai Hospital Faculty of Medicine, University of Toronto Suite L6-201 200 Elizabeth Street 1 King’s College Circle, Rm 6231 60 Murray Street Toronto, Ontario, Canada M5G 2C4 Toronto, Ontario, Canada M5S 1A8 Toronto, Ontario, Canada M5T 3L9 Contact Information Mail Address: Box 32 60 Murray Street Mount Sinai Hospital Toronto, ON, Canada M5T 3L9 Telephone: 416-586-8443; Fax: 416-619-5521; Mobile: 416-505-2844 E-Mail: [email protected] Web Site: http:/www.acdcLab.org/ Curriculum Vitae — Eleftherios P. Diamandis Page 2 Table of Contents Date and Place of Birth ....................................................................................................... 4 Elementary Education ......................................................................................................... 4 Citizenship Status ............................................................................................................... 4 Degrees ............................................................................................................................... 4 Present Positions ................................................................................................................. 4 Cross-Appointments ........................................................................................................... 4 Previous Positions ............................................................................................................... 4 Distinctions and Awards ..................................................................................................... 5 Certifications ....................................................................................................................... 6 Society Memberships .......................................................................................................... 6 Experience in Education ..................................................................................................... 6 University of Athens, Greece ................................................................................ 6 University of Toronto, Canada ............................................................................. 7 Other University Activities ................................................................................................. 7 Organization of Scientific Meetings ................................................................................... 7 Organization of Workshops ................................................................................................ 8 Journal Referee ................................................................................................................... 9 Referee for Granting Agencies ......................................................................................... 11 Member of Scientific Advisory / Editorial Boards ........................................................... 11 Other Professional Activities ............................................................................................ 12 Direction of PhD and MSc Theses .................................................................................... 12 The Research Laboratory of Dr. Eleftherios P. Diamandis [April 2013] ......................... 14 Research Coordinator: ........................................................................................ 14 Research Technicians ......................................................................................... 15 Research Co-Investigators: ................................................................................. 15 Mass Spectrometry & Bioinformatics Specialists: ............................................. 15 Post-Doctoral Fellows: ....................................................................................... 15 PhD Candidates: ................................................................................................. 15 MSc Candidates: ................................................................................................. 15 Clinical Research Associates: ............................................................................. 15 Special Students: ................................................................................................. 15 Research Associates and Post-Doctoral Fellows .............................................................. 15 Past Post-Doctoral Fellows ................................................................................. 15 Past Medical Residents ....................................................................................... 16 Past Research Assistants ..................................................................................... 16 Past Undergraduate/Co-Op Students .................................................................. 17 Past Summer Students & Volunteers .................................................................. 17 Committee Member of Graduate Students .......................................................... 19 Research Grants ................................................................................................................ 20 Invited Lectures — National and International Events ..................................................... 25 Invited Lectures — Local and Commercial Events .......................................................... 33 Invited Lectures — Clinical Rounds ................................................................................. 35 Roundtables ...................................................................................................................... 35 Webinars ........................................................................................................................... 35 Interviews: Media Publications & Press Releases ............................................................ 35 Podcasts ............................................................................................................................ 38 List of Publications: Books .............................................................................................. 39 Book Chapters ................................................................................................................... 39 Reviews ............................................................................................................................. 41 Original Research Papers .................................................................................................. 48 Editorials/Commentaries/Perspectives/Reflections/Opinions........................................... 82 Questions and Answers ..................................................................................................... 85 Letters to the Editor .......................................................................................................... 86 Science Fiction .................................................................................................................. 88 Patents ............................................................................................................................... 88 GenBank Submissions ...................................................................................................... 90 Curriculum Vitae — Eleftherios P. Diamandis Page 3 Abstracts ........................................................................................................................... 92 Curriculum Vitae — Eleftherios P. Diamandis Page 4 Date and Place of Birth October 8, 1952 in Limassol, Cyprus Elementary Education Elementary and High School in Limassol, Cyprus. Graduation, June 1970. Citizenship Status Citizen of Canada Citizen of Cyprus Degrees 1972-76 B.Sc. Chemistry, University of Athens, Greece 1976-79 Ph.D. Analytical Chemistry, University of Athens, Greece 1982-84 Clinical Biochemistry Diploma University of Toronto, Canada 1978-82, 1984-86 M.D. University of Athens, Greece Present Positions Division Head, Clinical Biochemistry, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada [1995 to present] Professor and Head, Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Ontario, Canada [1997 to present] Biochemist-in-Chief, Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada [2005 to present] Hold'em for Life Chair in Prostate Cancer Biomarkers [2010 to present] Cross-Appointments Department of Surgery, Faculty of Medicine, University of Toronto [2006 to present] Previous Positions Dates Position Held 1970-1972 Served in the Cyprus Army. Aug 1976 - Jan 1978 Post-graduate student, Hellenic National Research Foundation. Jan 1978 - Oct 1979 Research Assistant, Laboratory of Analytical Chemistry, University of Athens. Nov 1979 - Aug 1982 Instructor, Laboratory of Analytical Chemistry, University of Athens. Jul - Sep 1981 Post-Doctoral Research Associate, University of Illinois, Urbana-Champaign, USA Sep 1982 - Aug 1983 Trainee in Clinical Biochemistry, The Hospital for Sick Children, Toronto. Sep 1983 - Mar 1984 Trainee in Clinical Biochemistry, Mount Sinai Hospital, Toronto. Apr 1984 - Jul 1984 Trainee
Load more

Recommended publications
  • Breast Cysts
    Beaumont Hospital Patient Information on Breast Cysts PRINTROOM PDF 23012017 SUP190B What are breast cysts? The breasts are made up of lobules (milk- producing glands) and ducts (tubes that carry milk to the nipple), surrounded by fatty and supportive tissue. Sometimes fluid-filled sacs develop in the breast tissue. These are breast cysts. It’s thought that they develop naturally as the breast ages and changes. Although you can develop breast cysts at any age, they are most common in women over 35 who haven’t yet reached menopause. They occur more frequently as women approach the menopause and usually resolve or are less frequent after it. However, they may persist or develop in women who take hormone replacement therapy (HRT) after menopause. Cysts can feel soft if they are near the surface of the skin, or like a hard lump if they’re deeper in the breast tissue. They can develop anywhere in the breast, but are more commonly found in the upper half. For some women cysts can feel uncomfortable or even painful. Before a period cysts may become larger, and feel sore and tender. It’s common to develop one or more cysts either in one breast or both breasts –and this is nothing to worry about. It is also common to have many cysts without knowing about them. How are they found? Cysts usually become noticeable as a lump in the breast, or are sometimes found by chance when you have a breast examination or routine mammography. When you have a breast examination your GP will sometimes be able to say whether the lump feels like a cyst.
    [Show full text]
  • Approach to Breast Mass
    APPROACH TO BREAST MASS Resident Author: Kathleen Doukas, MD, CCFP Faculty Advisor: Thea Weisdorf, MD, CCFP Creation Date: January 2010, Last updated: August 2013 Overview In primary care, breast lumps are a common complaint among women. In one study, 16% of women age 40-69y presented to their physician with a breast lesion over a 10-year period.1 Approximately 90% of these lesions will be benign, with fibroadenomas and cysts being the most common.2 Breast cancer must be ruled out, as one in ten woman who present with a new lump will have cancer.1 Diagnostic Considerations6 Benign: • Fibroadenoma: most common breast mass; a smooth, round, rubbery mobile mass, which is often found in young women; identifiable on US and mammogram • Breast cyst: mobile, often tender masses, which can fluctuate with the menstrual cycle; most common in premenopausal women; presence in a postmenopausal woman should raise suspicion for malignancy; ultrasound is the best method for differentiating between a cystic vs solid structure; a complex cyst is one with septations or solid components, and requires biopsy • Less common causes: Fat necrosis, intraductal papilloma, phyllodes tumor, breast abscess Premalignant: • Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia: Premalignant breast lesions with 4-6 times relative risk of developing subsequent breast cancer;8 often found incidentally on biopsy and require full excision • Carcinoma in Situ: o Ductal Carcinoma in Situ (DCIS): ~85% of in-situ breast cancers; defined as cancer confined to the duct that
    [Show full text]
  • Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience
    Article Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience Eiji Higashihara,*† Vicente E. Torres,*‡ Arlene B. Chapman,§ Jared J. Grantham, Kyongtae Bae,¶ Terry J. Watnick,** †† † ‡‡ ‡‡ ‡‡ 2 Shigeo Horie, Kikuo Nutahara, John Ouyang, Holly B. Krasa, Frank S. Czerwiec, for the TEMPO4 and 156-05-002 Study Investigators Summary †Kyorin University Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of School of Medicine, end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression Mitaka, Tokyo, Japan; ‡ in animal models. Mayo Clinic College of Medicine, Rochester, Minnesota; §Emory Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kid- University School of ney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of Medicine, Atlanta, ʈ tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, Georgia; Kansas and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR University Medical Center, Kansas City, (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses Kansas; ¶University of of primary and secondary end points included LMM using all subject data and mixed model repeated mea- Pittsburgh School of sures (MMRM) of change from baseline at each year. Pearson correlation tested the association between Medicine, Pittsburgh, log-TKV and eGFR changes. Pennsylvania; **Johns Hopkins University, Baltimore, Maryland; Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events ††Teikyo University (AEs), with AEs accounting for six of 12 withdrawals.
    [Show full text]
  • Index to the NLM Classification 2011
    National Library of Medicine Classification 2011 Index Disease see Tyrosinemias 1-8 5,12-diHETE see Leukotriene B4 1,2-Benzopyrones see Coumarins 5,12-HETE see Leukotriene B4 1,2-Dibromoethane see Ethylene Dibromide 5-HT see Serotonin 1,8-Dihydroxy-9-anthrone see Anthralin 5-HT Antagonists see Serotonin Antagonists 1-Oxacephalosporin see Moxalactam 5-Hydroxytryptamine see Serotonin 1-Propanol 5-Hydroxytryptamine Antagonists see Serotonin Organic chemistry QD 305.A4 Antagonists Pharmacology QV 82 6-Mercaptopurine QV 269 1-Sar-8-Ala Angiotensin II see Saralasin 7S RNA see RNA, Small Nuclear 1-Sarcosine-8-Alanine Angiotensin II see Saralasin 8-Hydroxyquinoline see Oxyquinoline 13-cis-Retinoic Acid see Isotretinoin 8-Methoxypsoralen see Methoxsalen 15th Century History see History, 15th Century 8-Quinolinol see Oxyquinoline 16th Century History see History, 16th Century 17 beta-Estradiol see Estradiol 17-Ketosteroids WK 755 A 17-Oxosteroids see 17-Ketosteroids A Fibers see Nerve Fibers, Myelinated 17th Century History see History, 17th Century Aardvarks see Xenarthra 18th Century History see History, 18th Century Abate see Temefos 19th Century History see History, 19th Century Abattoirs WA 707 2',3'-Cyclic-Nucleotide Phosphodiesterases QU 136 Abbreviations 2,4-D see 2,4-Dichlorophenoxyacetic Acid Chemistry QD 7 2,4-Dichlorophenoxyacetic Acid General P 365-365.5 Organic chemistry QD 341.A2 Library symbols (U.S.) Z 881 2',5'-Oligoadenylate Polymerase see Medical W 13 2',5'-Oligoadenylate Synthetase By specialties (Form number 13 in any NLM
    [Show full text]
  • Research Article Application Value of Mathematical Models of Diffusion-Weighted Magnetic Resonance Imaging in Differentiating Breast Cancer Lesions
    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2021, Article ID 1481271, 8 pages https://doi.org/10.1155/2021/1481271 Research Article Application Value of Mathematical Models of Diffusion-Weighted Magnetic Resonance Imaging in Differentiating Breast Cancer Lesions Xiaolong Jiang, Chao Chen, Jie Liu, and Sheng Liu e Affiliated Nanhua Hospital, Department of Radiology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China Correspondence should be addressed to Sheng Liu; [email protected] Received 7 July 2021; Accepted 17 August 2021; Published 30 August 2021 Academic Editor: Songwen Tan Copyright © 2021 Xiaolong Jiang et al. ,is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To determine the application value of the mono-exponential model, dual-exponential model, and stretched-exponential model of MRI with diffusion-weighted imaging (DWI) in breast cancer (BC) lesions. Methods. Totally 64 cases with BC admitted to our hospital between June 2019 and October 2020 were enrolled in this study. ,ey had 71 lesions in total, including 40 benign tumor lesions (including 9 breast cyst lesions) and 31 malignant tumor lesions. After DWI examination, with normal glands as control, mono-exponential model (ADC) map, dual-exponential model (Standard-ADC) map, slow apparent diffusion coefficient (Slow- ADC) map, fast-apparent diffusion coefficient (Fast-ADC) map, and stretched-exponential model (DDC) map were processed, and corresponding values were generated. ,en, the situation and significance of each parameter in breast cysts, benign breast tumor lesions, and malignant tumor lesions were analyzed.
    [Show full text]
  • Professor Julie Audet<B>
    University of Toronto Faculty, Staff, and Student Awards and Honours Governing Council Meeting October 23, 2008 Faculty & Staff Awards Professor Emeritus Paul Aird of forestry is the winner of the Endangered Species Stewardship Award, presented to him by Donna Cansfield, Ontario minister of natural resources, at a natural History Day event, held May 24 at Bonnechere Provincial Park in Renfrew County. Aird was honoured for his volunteer contributions related to Kirtland’s Warbler over the past 30-plus years, not only raising public awareness for this particular species at risk but for having made an important contribution towards recovery of this globally rare bird in Ontario. Keith Ambachtsheer, director of the Rotman International Centre for Pension Management, is the recipient of the James R. Vertin Award, given by the CFA (chartered financial analyst) Institute to recognize individuals who have produced a body of research notable for its relevance and enduring value to investment professionals. Ambachtsheer received the award July 22 at the 50th Financial Analysts Seminar, a CFA Institute conference hosted by the CFA Society of Chicago. Francesca Andrade of financial services is this year’s winner of U of T Scarborough’s Patrick Phillips Staff Award for outstanding service and commitment by a campus staff member, while Svetlana Mikhaylichenko of physical and environmental sciences is the recipient the D.R. Campbell Merit Award for enhancing the quality of life on campus. Professor Janet Potter of physical and environmental sciences is the winner of the Faculty Teaching Award. The Principal’s Awards were presented in June at an event hosted by Principal Franco Vaccarino.
    [Show full text]
  • 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
    Case 2:16-cv-02373-SPL Document 1 Filed 07/15/16 Page 1 of 36 1 Mark D. Samson Ron Kilgard 2 KELLER ROHRBACK L.L.P. 3 3101 North Central Ave., Suite 1400 Phoenix, AZ 85012 4 Phone: (602) 248-0088, Fax (602) 248-2822 5 [email protected] [email protected] 6 Lynn Lincoln Sarko (pro hac vice application forthcoming) 7 Gretchen Freeman Cappio (pro hac vice application forthcoming) 8 T. David Copley 1201 Third Avenue, Suite 3200 9 KELLER ROHRBACK L.L.P. 10 Seattle, WA 98101-3052 (206) 623-1900, Fax (206) 623-3384 11 [email protected] [email protected] 12 [email protected] 13 Attorneys for Plaintiffs 14 15 UNITED STATES DISTRICT COURT DISTRICT OF ARIZONA 16 R.C., individually and on behalf of all others 17 similarly situated, No. 18 Plaintiff, 19 CLASS ACTION COMPLAINT v. 20 JURY TRIAL DEMANDED THERANOS, INC., a California 21 Corporation, and WALGREENS BOOTS 22 ALLIANCE, INC., a Delaware Corporation, 23 Defendants. 24 25 26 27 COMPLAINT 28 1 Case 2:16-cv-02373-SPL Document 1 Filed 07/15/16 Page 2 of 36 1 I. INTRODUCTION 2 1. Blood tests are a critical component of a patient’s healthcare. Patients, as well as 3 their doctors, rely on blood tests to detect conditions and use those results to help determine which 4 course of treatment is or isn’t needed. Inaccurate blood test results can contribute to serious 5 6 conditions going undetected, to treatable conditions growing worse unnoticed, to patients forgoing 7 medications they should take or taking medications they shouldn’t.
    [Show full text]
  • DRUG DISCOVERY SUMMIT: Enabling Early Stage Drug Discovery and Venture Creation
    PRESENT: DRUG DISCOVERY SUMMIT: Enabling Early Stage Drug Discovery and Venture Creation Event Program JLABS@Toronto Tuesday June 11, 2019 MaRS Centre, West Tower 1:00 – 6:00 PM 661 University Avenue, Suite 1300 Toronto, ON, Canada M5G 0B7 POWERED BY: WELCOME MaRS Innovation and our partner Evotec SE are pleased to welcome you to our inaugural LAB150 Drug Discovery Summit. We would like to thank Allan Miranda and the JLABS team for hosting us here today in this spectacular facility! It has been 18 months since we launched LAB150, a program designed to enable translation of academic discoveries into medicines from MaRS Innovation (MI) Members. With five projects approved and funded and one project graduated from the program and negotiating follow-on investment, we are off to an incredible start! The LAB150 program, paired with MI’s venture creation and investment model, provides a leading platform for life sciences venture creation and growth in Canada. Over the last decade, MI has created over 50 companies that have attracted and retained seasoned management, created over 400 STEM jobs and raised over $350M in direct third-party capital. With LAB150, we look forward to building on this success in the coming decade and beyond. Today you will hear from entrepreneurs and scientists regarding their experiences with the LAB150 program. In addition, we are pleased to be joined by scientific experts from Evotec who will share emerging trends in the drug discovery space. Last but not least, early stage investors will share their tips and tricks for securing capital for building therapeutic ventures in Canada.
    [Show full text]
  • Benign Breast Cyst Without Associated Gynecomastia in a Male Patient: a Case Report Parsian Et Al
    Breast Imaging: Benign Breast Cyst without Associated Gynecomastia in a Male Patient: A Case Report Parsian et al. Benign Breast Cyst without Associated Gynecomastia in a Male Patient: A Case Report Sana Parsian1*, Habib Rahbar1, Mara H. Rendi2, Constance D. Lehman1 1. Department of Radiology, University of Washington, Seattle, USA 2. Department of Pathology, University of Washington, Seattle, USA * Correspondence: Sana Parsian, MD., Department of Radiology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue E. Seattle, WA 98109, USA ( [email protected]) Radiology Case. 2011 Nov; 5(11):35-40 :: DOI: 10.3941/jrcr.v5i11.869 ABSTRACT Benign simple breast cysts are commonly seen in female breasts and can present as palpable masses. They are distinctly uncommon, however, in the male breast. We report a case of simple benign cyst of the breast in a 58- year-old man newly diagnosed with mantel cell lymphoma. The cyst was first identified incidentally on a staging contrast-enhanced chest computed www.RadiologyCases.com tomography. Further evaluation with mammography and ultrasound revealed a mass that would be typically characterized as a benign simple cyst, but was biopsied since cysts are not known to occur in male breasts. Pathology results from ultrasound-guided core needle biopsy revealed benign cyst and focal fibrosis which was concordant with the imaging findings. In this case report, we will briefly discuss breast cysts in men and their imaging features including mammography and ultrasound. CASE REPORT JournalRadiology of Case Reports Bilateral diagnostic digital mammogram revealed a 10 CASE REPORT millimeter oval shaped equal density mass with partially A 58-year-old Caucasian man, with recent diagnosis of circumscribed, partially obscured margins in the subareolar mantle cell lymphoma underwent chest, abdomen, and pelvis left breast, corresponding to the CT finding, without evidence computed tomography (CT) for staging purposes.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
    [Show full text]
  • Theranos Phenomenon – Part 5: Theranos’ Presentation at the American Association for Clinical Chemistry Annual Conference 2016
    Clin Chem Lab Med 2016; 54(10): e313–e314 Letter to the Editor Eleftherios P. Diamandis* and Mario Plebani Theranos phenomenon – Part 5: Theranos’ presentation at the American Association for Clinical Chemistry Annual Conference 2016 DOI 10.1515/cclm-2016-0737 Master, two highly recognized and respected clinical Accepted for publication August 18, 2016; previously published chemists, who did a good job in asking pertinent ques- online August 30, 2016 tions to Ms. Holmes and her associates. In this respect, AACC lived up to the expectations of high standards and Keywords: diagnostics; new technologies. impartiality for this presentation. Holmes presented to a large and curious, if not To the Editor, hostile, audience. She avoided talking about Theranos’ past and the difficulties of her company [1–7]. She also The widely anticipated presentation of Theranos at the made it clear that her presentation would focus on the Annual Conference of the American Association for future, not the past, and she distanced herself from the Clinical Chemistry (AACC) was finally given on Monday, previous “Edison” instrument and introduced a new August 1st, 2016 at the Philadelphia Convention Center. analyzer named “MiniLab”. In the first part of her pres- This journal has followed the Theranos story closely over entation, Ms. Holmes described the engineering behind the last 2 years and provided frequent updates [1–4]. Eliza- the MiniLab and explained that it is a compact desktop beth Holmes, the Chief Executive of Theranos, presented device that houses a mini spectrophotometer, a mini- to an audience of over 2500 clinical chemists and other luminometer, and mini-flow-cytometer and a mini-PCR laboratory scientists, as well as to an impressive number machine, along with a centrifuge.
    [Show full text]
  • 65 Y/O Female, Lower Abdominal Pain A19
    2016年05月20日 中華民國放射線醫學會 住院醫師閱片測驗 出題醫院 亞東紀念醫院影像醫學科 Q1 What is most likely in a 35-year-old patient? CT with bone window T1 weighted with Gd A1 What bone lesion is most likely in this 35-year-old female? ANS： Fibrous dysplasia Q2 76y/o male, patient with severe headache What is the diagnosis & its cause in this case? FLAIR or dark-fluid T2 Pre-contrast T1 weighted A2 ANS： Acute venous infarct & left transverse sinus thrombosis Q3 What primitive carotid-vertebrobasilar connection is? The red arrow is the left carotid artery A3 ANS： Persistent trigeminal artery Q4 11 y/o boy, with seizure Coronal T2 weighted Sagittal T1 weighted with Gd. A4 ANS： Ependymoma Q5 42 y/o male, patient with head injury FLAIR or dark water T2 T1 weighted with Gd. A5 ANS： Enlarged perivascular space or dilated Virchow-Robin space Q6 44 y/o male, Right homonymous hemianopia for 7 days DWI ADC T1 FLAIR T2 CE T1 A6 ANS： Subacute infarction at left occipital lobe Q7 69 y/o male, 到院前心跳停止, Acute conscious change, sent to ER A7 ANS： Hypoxic ischemic encephalopathy Q8 50 y/o female, Orthostatic headache A8 ANS： Spontaneous Intracranial Hypotension Spontaneous Intracranial Hypotension • Syndrome in which low CSF volume results in orthostatic headache • Generally due to CSF leakage through a dural defect • May be related to predisposing underlying structural weakness of the spinal meninges • Key Imaging Features: related to Monro-Kellie hypothesis: loss of CSF from subarachnoid space → increase in total intracranial blood volume causing enlargement of dural venous sinuses, epidural vertebral venous plexus, and pituitary gland.
    [Show full text]